Get the Stockscreener App
0.03
73.55%
-0.0872
After Hours:
.03
Syros Pharmaceuticals Inc stock is traded at $0.03, with a volume of 149.41K.
It is down -73.55% in the last 24 hours and down -79.82% over the past month.
See More
Previous Close:
$0.1172
Open:
$0.0268
24h Volume:
149.41K
Relative Volume:
66.00
Market Cap:
$N/A
Revenue:
$9.94M
Net Income/Loss:
$-144.49M
P/E Ratio:
-0.00594
EPS:
-5.05
Net Cash Flow:
$-103.90M
1W Performance:
-73.55%
1M Performance:
-79.82%
6M Performance:
-98.42%
1Y Performance:
-99.50%
1-Day Range:
$0.0257
$0.03
1-Week Range:
$0.0257
$0.03
52-Week Range:
$0.0257
$0.03
Syros Pharmaceuticals Inc Stock (SYRS) Company Profile
Name
Syros Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare SYRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SYRS
Syros Pharmaceuticals Inc
|
0.03 | 0 | 9.94M | -144.49M | -103.90M | -5.05 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Syros Pharmaceuticals Inc Stock (SYRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| Jan-17-20 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-08-19 | Resumed | JMP Securities | Mkt Outperform |
| Feb-14-19 | Resumed | Oppenheimer | Outperform |
| Nov-05-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Mar-13-18 | Reiterated | Wedbush | Outperform |
| Oct-31-17 | Resumed | Piper Jaffray | Overweight |
| Oct-23-17 | Initiated | ROTH Capital | Neutral |
| Aug-10-17 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
View All
Syros Pharmaceuticals Inc Stock (SYRS) Latest News
SYROS PHARMACEUTICALS Earnings Preview: Recent $SYRS Insider Trading, Hedge Fund Activity, and More - Nasdaq
Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by StockNews.com - Defense World
Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight - GlobeNewswire Inc.
Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated by Analysts at StockNews.com - Defense World
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
StockNews.com Begins Coverage on Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
StockNews.com Initiates Coverage on Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World
Rege Nephro buys Tamibarotene-related assets from Syros Pharmaceuticals - MSN
Rege Nephro Acquires Assets from Syros Pharmaceuticals (SYRS) - GuruFocus
Rege Nephro Acquires Key Assets from Syros Pharmaceuticals (SYRS - GuruFocus
Rege Nephro Acquires Key Assets from Syros Pharmaceuticals (SYRS) | SYRS Stock News - GuruFocus
Major Kidney Disease Drug Acquisition: Rege Nephro Takes Over Syros' Phase 2 Asset - Stock Titan
Rege Nephro Acquires Tamibarotene-Related Assets from Syros Phar - GuruFocus
Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials - digitalmore.co
Syros Pharma pulls out of deal with RaQualia - The Pharma Letter
Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated at StockNews.com - Defense World
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Given Average Recommendation of “Hold” by Brokerages - Defense World
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Short Interest Up 345.9% in March - Defense World
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives $3.33 Average PT from Brokerages - Defense World
Syros Pharmaceuticals (SYRS) to Release Earnings on Wednesday - Defense World
Dow Dips Over 200 Points; US Industrial Production Increases More than Expected - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga India
Analyze Syros Pharmaceuticals Inc (NASDAQ: SYRS) Before Investing. - stocksregister.com
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - Citeline News & Insights
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Pre-market Movers: HCTI, HEPA, ZYXI, SYRS ... - RTTNews
US Stocks Mixed; Kohl's Shares Plunge After Q4 Results - Benzinga
Aptevo Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:APVO - Benzinga
Syros Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Syros Pharmaceuticals settles debt with Oxford Finance By Investing.com - Investing.com South Africa
Syros Pharmaceuticals settles debt with Oxford Finance - Investing.com India
Why US Stock Futures Are Rising TodayInvesco QQQ Trust, Series 1 (NASDAQ:QQQ), SPDR S&P 500 (ARCA:SPY) - Benzinga
Syros Pharmaceuticals, Inc. Announces Cessation of Gerald Quirk as Chief Executive Officer, Effective March 01, 2025 - Marketscreener.com
Syros Pharmaceuticals, Inc. Announces Management Changes -February 28, 2025 at 04:15 pm EST - Marketscreener.com
Stocks to Watch: Toro, Syros Pharmaceuticals - MarketWatch
Syros to delist from Nasdaq, deregister from SEC - MSN
Syros Pharmaceuticals Delists from Nasdaq Amid Restructuring - TipRanks
Syros Pharmaceuticals to Delist from Nasdaq, Deregister Common Shares -February 28, 2025 at 04:41 pm EST - Marketscreener.com
Syros Pharmaceuticals voluntarily delists from Nasdaq, deregisters common stock - TipRanks
Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration - Business Wire
Syros Pharmaceuticals Inc Stock (SYRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Cap:
|
Volume (24h):